It hasn't quite been one year since Medigene AG made Dolores Schendel its CEO, consolidating its position as a fully immune-oncology focused biotech. However, the recent deal with bluebird bio Inc. will be seen as the official launch of Medigene as an anticancer player.
The deal is centered around Medigene's T cell receptor (TCR) discovery platform. The platform was one of three that the German firm acquired when it bought Trianta Immunotherapies in 2014. Trianta's CEO was Dolores Schendel
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?